~~<i id='2A414453C5'><strike id='2A414453C5'><tt id='2A414453C5'><pre id='2A414453C5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

explore

author：Wikipedia 2025-10-01 02:15:19 - browse：7629

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA greenlights medical device to combat bladder issues

entertainment

knowledge

focus

leisure time

focus

hotspot

CantheFDAbetooflexible?Howdoyoutestamechanicalwomb?Andwhodecideswhat’sgoodenoughforpatientsinneed?We

WSS

Ukraine and a new approach to mental health in war

Biotech stock slump in 2023: awaiting the turnaround

Emergency workers more likely to restrain Black patients: study

How AI helped researchers track recovery from depression

As obesity drug market grows, telehealth companies court payers

How the drug

Wikipedia

explore

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Affirmative action in medical school literally saved lives

EpiPen alternative approval delay highlights citizen petition issue

What does generative AI mean for health care? We asked experts

Second xenotransplant done with gene

Medicare details structure of new drug price negotiation program

How AI helped researchers track recovery from depression

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: possible new ALS drug, artificial wombs

knowledge

Wegovy improves function in certain heart failure patients

Hearing on Medicare drug price negotiation gets unusually heated

Experts study whether long Covid risk adds up with each reinfection

Vivek Ramaswamy made waves in the debate, much as in biotech

Listen: Vivek Ramaswamy's star turn & leaky drug data

Hearing on Medicare drug price negotiation gets unusually heated

focus

leisure time

focus

hotspot